New test to reduce antibiotics in primary care

Image source: Adobe Stock/Have a nice day

News • Resistance building prevention

New test to reduce antibiotics in primary care

In human medicine, antibiotics are most commonly used in primary care, particularly for respiratory and urinary tract infections. But it is precisely for these illnesses that patients are often prescribed antibiotics unnecessarily. This facilitates the emergence of antibiotic resistance.

That is why researchers at the University of Basel led by Heiner C. Bucher are specifically sensitising family doctors, who prescribe antibiotics more often than others. The problem is that their antibiotic use is not systematically recorded. But Bucher and his team have found a solution in a project of the National Research Programme "Antimicrobial Resistance" (NRP 72) supported by the Swiss National Science Foundation (SNSF): the billing data of health insurance companies can tell us when, to what end and in which doctor's surgery individual patients were prescribed antibiotics. Therefore, by analysing sufficient patient data, researchers can draw conclusions about physicians' prescribing practices. 

Their findings are published at Lancet preprints.

We’ve shown that you can continuously track antibiotic use in primary care [...] in a way that doesn't create any extra work for primary care physicians

Soheila Aghlmandi

For their study, the researchers had access to anonymised data from the three largest Swiss insurers. "Even though we didn't see the names or addresses, we were able to match all antibiotic prescriptions to specific physicians," says member of the project team Soheila Aghlmandi. "And if some doctors prescribed a lot of antibiotics, we could send them feedback without identifying them personally." To do this, however, Bucher and his team first had to develop automated workflows that bring together all the necessary information from the different data formats and structures of the respective insurers – an enormous effort given the more than 1.3 million patients with a total of more than 4 million consultations. 

But the researchers conducting the project were able to overcome all technical hurdles. They sent feedback to more than 1500 physicians with rather high antibiotic use every three months. In addition, they informed them – also anonymously – at the beginning of the study about the current resistance situation and the average antibiotic consumption of other surgeries in their region. During the two-year study, however, the measures did not lead to an improvement in prescribing practices. But Aghlmandi is still satisfied with the results. "We’ve shown that you can continuously track antibiotic use in primary care," she says. "And in a way that doesn't create any extra work for primary care physicians." The method could be expanded into a nationwide monitoring system. Aghlmandi stresses, however, that this would require all health insurers to provide the relevant data; moreover, technical solutions for merging that data would need to be developed first. 

A further measure to optimise antibiotic prescribing for respiratory tract infections has been tested in another NRP 72 project by researchers at Lausanne University Hospital (CHUV) led by Noémie Boillat Blanco. Their approach focuses on diagnosis. This is because doctors often cannot determine from symptoms alone whether pneumonia is bacterial, requiring antibiotic therapy, or a non-bacterial infection that will subside by itself. Boillat Blanco and her team developed an approach in which a lung ultrasound is combined with a procalcitonin test that helps to differentiate between bacterial and viral infections. Since each method on its own provides too many uncertain diagnoses, they combined the results using an algorithm to increase precision. 

In a pragmatic study lasting several months, thirty family doctors applied the new procedure to all patients who presented with symptoms of a respiratory tract infection. The results did indeed show a reduction in the number of antibiotic prescriptions of one third. Surprisingly, however, use of the procalcitonin test alone proved to be sufficient for a reduction of this magnitude. Indeed, the procalcitonin result was low in the majority of patients, and no antibiotics were recommended in these cases. Additional ultrasound scans were limited to patients with high procalcitonin and therefore rarely performed. 

The lower antibiotic prescriptions had no negative impact on patient recovery. "This means we can significantly reduce antibiotic prescriptions with the procalcitonin test without compromising treatment quality," says Noémie Boillat Blanco. Based on these results, the Swiss Society for Infectious Diseases has included the procalcitonin test in its guidelines for the management of pneumonia. 

However, whether it catches on will depend not least on whether health insurers are willing to pay for it. To facilitate this, Boillat Blanco's team has shown in another study that the approach is cost-effective. The test could therefore soon be used on a larger scale throughout Switzerland. Whether and how this has an overall impact on antibiotic prescriptions by general practitioners could in turn be examined through nationwide monitoring. 


Source: Swiss National Science Foundation

04.10.2022

Read all latest stories

Related articles

Photo

News • Elusive variants

Rare genetic markers of drug-resistant tuberculosis identified

The search for rare mutations in bacterial genome could lead to better diagnostics and treatments – reducing morbidity caused by the deadly disease.

Photo

News • Alternative therapy

Potent nanodrug combast antibiotic-resistant infections

A research team led by University of Arkansas chemist Jingyi Chen and University of Arkansas for Medical Sciences microbiologist Mark Smeltzer has developed an alternative therapeutic approach to…

Photo

Article • Politics

Antibiotic resistance is a threat to global health

Within 15 years effective antibiotics will run out and, far from being an apocalyptic fantasy, a world in which common infections and minor injuries can kill is a very real possibility for the 21st…

Related products

IBA Dosimetry – Spot-Luminance meter LXcan

Testing Devices

IBA Dosimetry – Spot-Luminance meter LXcan

IBA Dosimetry GmbH
Nova Biomedical – StatStrip Glucose/Ketone*

Blood Glucose

Nova Biomedical – StatStrip Glucose/Ketone*

Nova Biomedical Corporation
Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Clinical Chemistry

Alsachim – Dosinaco anticoagulant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Beckman Coulter – Access 2 Immunoassay System

Immunoassays

Beckman Coulter – Access 2 Immunoassay System

Beckman Coulter Diagnostics
Beckman Coulter – Access Procalcitonin (PCT)

Immunoassays

Beckman Coulter – Access Procalcitonin (PCT)

Beckman Coulter Diagnostics
Subscribe to Newsletter